Importance Obesity affects approximately 42% of US adults and is associated with increased
rates of type 2 diabetes, hypertension, cardiovascular disease, sleep disorders …

Hypoxia, characterized by reduced oxygen concentration, is a significant stressor that affects
the survival of aerobic species and plays a prominent role in cardiovascular diseases. From …

Background Obesity and type 2 diabetes are prevalent in patients with heart failure with
preserved ejection fraction and are characterized by a high symptom burden. No approved …

Background Obesity increases the risk of heart failure with preserved ejection fraction.
Tirzepatide, a long-acting agonist of glucose-dependent insulinotropic polypeptide and …

The development of glucagon-like peptide 1 receptor agonists (GLP-1RA) for type 2
diabetes and obesity was followed by data establishing the cardiorenal benefits of GLP-1RA …

Abstract The glucagon-like peptide-1 (GLP-1) receptor, known as GLP-1R, is a vital
component of the G protein-coupled receptor (GPCR) family and is found primarily on the …

Obesity is a major public health crisis. Multi-specific peptides have emerged as promising
therapeutic strategies for clinical weight loss. Glucagon-like peptide-1 (GLP-1) and glucose …

Obesity and its comorbidities, including type 2 diabetes mellitus, cardiovascular disease,
heart failure and non-alcoholic liver disease are a major health and economic burden with …

Metabolic dysfunction-associated steatohepatitis (MASH) is a leading etiology of chronic
liver disease worldwide, with increasing incidence and prevalence in the setting of the …

The 2021 Update to the 2017 American College of Cardiology (ACC) Expert Consensus
Decision Pathway for Optimization of Heart Failure Treatment: Answers to 10 Pivotal Issues …